Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

(2018) Sara Mainardi et al.   NATURE MEDICINE

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor

(2016) Jorge Garcia Fortanet et al.   JOURNAL OF MEDICINAL CHEMISTRY

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

(2016) Ying-Nan P. Chen et al.   NATURE

A combinatorial strategy for treating KRAS-mutant lung cancer

(2016) Eusebio Manchado et al.   NATURE

Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation

(2016) Jian Zheng et al.   NATURE GENETICS

Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

(2015) P. Pettazzoni et al.   CANCER RESEARCH

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

(2015) Sylvia F. Boj et al.   CELL

Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo

(2015) Stefanie Grosskopf et al.   ChemMedChem

Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice

(2015) L. Lan et al.   EMBO JOURNAL

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

(2015) Pawel K Mazur et al.   NATURE MEDICINE

Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma

(2015) Valentina E. Schneeberger et al.   Oncotarget

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

(2015) Anirudh Prahallad et al.   Cell Reports

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

(2014) B. Alagesan et al.   CLINICAL CANCER RESEARCH

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

(2014) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer

(2014) Nina Schönhuber et al.   NATURE MEDICINE

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma

(2013) Jie Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer

(2013) Stefan Eser et al.   CANCER CELL

Roles for KRAS in Pancreatic Tumor Development and Progression

(2013) Marina Pasca di Magliano et al.   GASTROENTEROLOGY

Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice

(2012) C.-L. Lee et al.   Disease Models & Mechanisms

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

(2012) Eric A. Collisson et al.   Cancer Discovery

Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis

(2011) Emilie A. Bard-Chapeau et al.   CANCER CELL

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation

(2009) Takashi Matozaki et al.   CANCER SCIENCE

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

The tyrosine phosphatase Shp2 (PTPN11) in cancer

(2008) Gordon Chan et al.   CANCER AND METASTASIS REVIEWS

Protein tyrosine phosphatases in the JAK/STAT pathway

(2008) Dan Xu   Frontiers in Bioscience-Landmark

Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking

(2008) K. Hellmuth et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA